This is an outdated version published on 2021-05-30. Read the most recent version.

RELAÇÃO DOS ELEMENTOS BIOQUÍMICOS E FARMACOLÓGICOS COM O DESENVOLVIMENTO DE COMPLICAÇÕES CARDÍACAS EM PORTADORES DE COVID-19: REVISÃO DE LITERATURA

Authors

DOI:

10.46551/ruc.v23n1a01

Keywords:

COVID-19; SARS-CoV-2; Cardiovascular diseases

Abstract

Justification and Objectives: The choice for this theme is important because it is a recently discovered disease that is generating a great impact worldwide, and is therefore of high scientific relevance. The objective was to describe the biochemical and pharmacological elements and their relationship with the development or worsening of cardiac changes in patients with COVID-19. Content: This is an integrative literature review with search for articles in three databases: Medical Literature Analysis and Retrieval System Online (MEDLINE), Latin American Literature in Health Sciences (LILACS) and SUS collections consulted through the Library Virtual Health (BVS Brasil), from June 1 to 18, 2020. 11 articles comprised this review. A flowchart was made showing the following topics: data collection; selection of records; analysis of the selection by title or abstract;
eligibility assessment; studies included for the construction of the synoptic framework. Conclusion: There is a relationship between COVID-19 and the development and / or worsening of cardiovascular changes, this relationship can be mediated by the action of the angiotensin-converting enzyme (ACE 2) and elevated levels of D-dimers. Patients with cardiovascular, hypertensive and diabetics have higher expression of ACE 2, which contributed to increase the chance of becoming infected by the virus. It was not possible to confirm whether antihypertensive drugs are related to the development of COVID-19.

Downloads

Download data is not yet available.

Author Biographies

Bruna Katerine Goginho Gomes, Universidade Estadual de Montes Claros - Unimontes

Enfermeira pela Universidade Estadual de Montes Claros (UNIMONTES). 

Hilária Augusto Lopes Vieira, Universidade Estadual de Montes Claros - Unimontes

Enfermeira pela Universidade Estadual de Montes Claros (UNIMONTES). 

Ana Paula Ferreira Maciel, Universidade Estadual de Montes Claros - Unimontes

Mestre em Enfermagem pela Universidade Estadual de Montes Claros (UNIMONTES).

Vinícius Gomes e Martins, Centro Universitário FIPMoc - UNIFIPMoc

Graduando de Medicina pelo Centro Universitário FIPMoc (UNIFIPMoc). 

Aurelina Gomes e Martins, Universidade Federal de São Paulo - UNIFESP

Mestre em Enfermagem pela Universidade Federal de São Paulo (UNIFESP). 

Fernanda Sabrina Dias dos Santos, Faculdade de Saúde e Humanidades - FASI

Graduanda do curso de Biomedicina da Faculdade de Saúde e Humanidades (FASI).

Otávio Henrique Oliveira Macedo, Universidade Estadual de Montes Claros - Unimontes

Enfermeiro pela Universidade Estadual de Montes Claros (UNIMONTES).

Carla Silvana de Oliveira e Silva, Universidade Federal de São Paulo - UNIFESP

Pós-doutorado pela Universidade Federal de Saõ Paulo (UNIFESP).

References

TAO, C, et al. Clinical characteristics of 113 deceased patients with coronavirus

disease 2019: Retrospective study. BMJag., China. 12(1):3-17, mar.,2020.

doi:https://doi.org/10.1136/bmj.m1091. Access in: 16 jun. 2020.

CHEN, et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel

coronavirus pneumonia in Wuhan, China: a descriptive study. Mag. Lancet Published

Online 395: 507–13., January, 2020. doi:https://doi.org/10.1016/S0140-

(20)30211-7 . Access en: 16 jun.2020.

ZAID, A, et al. Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a

Trojan horse? Implications in cardiovascular complications related to SARS-CoV-2.American Physiological Society, Jerusalém, Israel. 318(5):1080-83, mar., 2020.

doi:https://doi.org/10.1152/ajpheart.00215.2020. Access in: 16 ago. 2020.

HUANG, Chaolin et al., Clinical features of patients infected with 2019 novel

coronavirus in Wuhan, China. Lancet Published Online 395: 497–506., Jan., 2020.

doi:https://doi.org/10.1016/S0140-6736(20)30183-5. Access in: 16 ago.2020.

DAVID, S. Hui et al., The continuing 2019-nCoV epidemic threat of novel

coronaviruses to global health — The latest 2019 novel coronavirus outbreak in

Wuhan, China. Rev. Elservier., 91 (2020) 264–266., Jan. 2020.

doi: https://doi.org/10.1016/j.ijid.2020.01.009. Access in: 16 ago.2020.

NA, Z et al., A Novel Coronavirus from Patients with Pneumonia in China, 2019. Mag.

N Engl J Med ; 382(8): 727-733., february, 2020. doi:10.1056/nejmoa2001017.

MINISTÉRIO DA SAÚDE (BR). Diretrizes para Diagnóstico e Tratamento da Covid19 Versão 1 Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos em

Saúde – SCTIE. Brasília-DF abril 2020. p 398. Access en: 16 jun.2020..

MORENO, M, et al., Cardiovascular repercussions of infection by the new SARSCoV-2 coronavirus (COVID-19). Mag.CorSalud, [S.l.], v. 12, n. 1, p. 3-17, abr. 2020.

doi:article/view/588/1113. Access en: 16 jun.2020.

MINISTÉRIO DA SAÚDE (BR). Protocolo de Manejo Clínico do Coronavírus

(Covid-19) na Atenção Primária à Saúde: Diretrizes para Diagnóstico e Tratamento da

Covid-19 Versão 9. Secretaria de Atenção Primária à Saúde (SAPS) Brasília-DF

maio2020. p 41. Access en: 16 jun.2020.

CHATE, RC et al., Presentation of pulmonary infection on CT in COVID-19: initial

experience in Brazil. J. bras. pneumol. [Internet]; 2020;46(2):e20200121. Apr., 2020.

doi:https://doi.org/10.36416/1806-3756/e20200121. Access in: 16 ago.2020.

LANA, Raquel Martins et al., The novel coronavirus (SARS-CoV-2) emergency and

the role of timely and effective national health surveillance. Cad. Saúde

Pública [Internet]; 36(3):e00019620. Epub., Mar, 2020. doi:

https://doi.org/10.1590/0102-311x00019620. Access in: 16 ago.2020.

MEHRA, MR, et al., Cardiovascular Disease, Drug Therapy, and Mortality in Covid19. Mag. N Engl J Med., 382(25): e102, Jun2020.

doi:/doi/full/10.1056/NEJMoa2007621. Access en: 16 jun.2020.

WANG, D, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019

Novel Coronavirus–Infected Pneumonia in Wuhan. JAMA., China. 323(11):1061–

Feb. 2020. doi:10.1001/jama.2020.1585. Access in: 16 ago. 2020.

WORLD, Health Organization. New coronavirus (2019-nCoV): status report- 15. Feb,

Available in: https://www.who.int/docs/default-source/coronaviruse/situationreports/20200204-sitrep-15-ncov.pdf. Access in: 16 ago. 2020.

SUN, P, et al. Understanding of COVID-19 based on current evidence. Mag. J

MedVirol. 92:548–551, 2020. doi:https://doi.org/10.1002/jmv.25722. Access en: 16

jun.2020.

HAN, Y, et al. Society for Cardiovascular Magnetic Resonance (SCMR) guidance for

the practice of cardiovascular magnetic resonance during the COVID-19 pandemic. J

Cardiovasc Magn Reson 22., 26 (2020)., Apr.,

doi:https://doi.org/10.1186/s12968-020-00628-w. Access in: 16 ago.2020.

HAN, Y, et al., Expert Consensus on Principles of Clinical Management of Patients

With Severe Emergent Cardiovascular Diseases During the COVID-19 Epidemic.

Mag. Circulation; 141(20): e810-e816, may.2020 May.

doi:10.1161/CIRCULATIONAHA.120.047011. Access en: 16 jun.2020.

ELKIND, MSV; Harrington RA; Benjamin IJ. The Role of the American Heart

Association in the Global COVID-19 Pandemic. Circulation. 2020;141(15):e743-e745.

doi: 10.1161 / CIRCULATIONAHA.120.046749. Access in: 16 ago. 2020.

ASKIN, Lutfu; Tanrıverdi Okan; Askin Husna Sengul. The Effect of Coronavirus

Disease 2019 on Cardiovascular Diseases. Arq. Bras. Cardiol. [Internet]. 2020 Mai

114(5):817-822. doi: http://dx.doi.org/10.36660/abc.20200273. Access in: 16

ago.2020.

CHENG, P, et al.,Cardiovascular Risks in Patients with COVID-19: Potential

Mechanisms and Areas of Uncertainty. Curr Cardiol Rep. 22, 34 (2020).

doi:/10.1007/s11886-020-01293-2. Access en: 16 jun.2020.

FREDERIC, S, et al. Use of drugs with a potential cardiac effect in the definition of

SARS-CoV-2 infection. Elsevier Masson France., França. 113 (5): 293–296, mai.,

doi: 10.1016 / j.acvd.2020.04.003. Access in: 16 ago. 2020.

GHEBLAWI, M, et al., Enzima Conversora de Angiotensina 2: Receptor SARS-CoV-2

e Regulador do Sistema Renina-Angiotensina; Comemorando o 20º aniversário da

descoberta do ACE2. Circ Res., 126: 1456–1474., apr., 2020.

doi:/10.1161/CIRCRESAHA.120.317015. Access en: 12 jun.2020.

ZHOU F, et al. Clinical course and risk factors for mortality of adult inpatients with

COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–

,march, 2020. doi:/10.1016/S0140-6736(20)30566-3. Access en: 16 jun 2020.

AKHMEROV, A; Marbán E. COVID-19 and the Heart. Circ Res., 126(10): 1443-

, mai., 2020. doi:/10.1161/CIRCRESAHA.120.317055. Access en: 12 jun.2020.

ZHENG, YY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. China.

, 259–260 (2020). doi:/10.1038/s41569-020-0360-5. Access in: 14 jun. 2020.

R, Ferrari; G. Di Pasquale; C. Rapezzi. Commentary: What is the relationship between

Covid-19 and cardiovascular disease?. Commentary., 310(2020) P167-168., July 2020.

doi: https://doi.org/10.1016/j.ijcard.2020.03.074. Access in: 16 ago.2020.

MUSHTAQ, H, et al., Structural Variations in Human ACE2 may Influence its

Binding with SARS-CoV-2 Spike Protein. J Med Virol., Pakistan.apr., 2020.

doi:https://doi.org/10.1002/jmv.25832 .Access en: 12 jun.2020.

GIUSEPPE, Mancia, et al., Renin–Angiotensin–Aldosterone System Blockers and the

Risk of Covid-19. N Engl J Med 2020; 382: 2431-2440., Jun, 2020.

doi:10.1056/NEJMoa2006923. Access in: 16 ago.2020.

TOUYZ RM, Li H, Delles C. ACE2 the Janus-faced protein – from cardiovascular

protection to severe acute respiratory syndrome-coronavirus and COVID-19. Clin Sci

(Lond)., United Kingdom. 134 (7): 747–750apr., 2020. doi:10.1042/CS20200363.

Access in: 12 jun. 2020.

IACCARINO, G, et al., Renin-Angiotensin System Inhibition in Cardiovascular

Patients at the Time of COVID19: Much Ado for Nothing? A Statement of Activity

from the Directors of the Board and the Scientific Directors of the Italian Society of

Hypertension.High Blood Press Cardiovasc Prev., 27, 105–108 (2020).

doi:10.1007/s40292-020-00380-3. Access en: 12 jun.2020.

Published

2021-05-30

Versions

How to Cite

GOMES, B. K. G.; VIEIRA, H. A. L.; MACIEL, A. P. F.; MARTINS, V. G. e; MARTINS, A. G. e; SANTOS, F. S. D. dos; MACEDO, O. H. O.; SILVA, C. S. de O. e. RELAÇÃO DOS ELEMENTOS BIOQUÍMICOS E FARMACOLÓGICOS COM O DESENVOLVIMENTO DE COMPLICAÇÕES CARDÍACAS EM PORTADORES DE COVID-19: REVISÃO DE LITERATURA. Revista Unimontes Científica, [S. l.], v. 23, n. 1, p. 1–16, 2021. DOI: 10.46551/ruc.v23n1a01. Disponível em: https://www.periodicos.unimontes.br/index.php/unicientifica/article/view/4268. Acesso em: 25 nov. 2024.